Welcome to SOFIE!
We’ve recently acquired Zevacor Pharma, an amazing commercial radiopharmacy and contract manufacturing organization focused on the supply of theranostics for personalized health. This is the most significant milestone and value inflection point in our company’s history.
For me, this transaction started at the Society of Nuclear Medicine and Molecular Imaging 2016, when I discovered Zevacor Pharma was for sale. Bringing a radiopharmacy network and CMO under our umbrella has always been a dream of SOFIE’s, so I worked with my management team and Board to go boldly forward to acquire Zevacor.
This year-long endeavor tested our small company in every way imaginable, but my clearest memory of our diligence period was receiving a daily call from my CTO, Melissa Moore, who undertook a whirlwind deep dive of all 16 sites in two weeks. With every report, she mentioned the great people of Zevacor, their dedication and determination, their pride in their work, and their strong belief that Zevacor Pharma was prime for growth to bring novel diagnostics and therapeutics to market to affect patient outcomes.